Initiate clinical development for the SER-155 program
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Checked
- 24 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Antibiotic resistant bacterial infections, bacteremia, & GvHD – Initiate clinical development H1 ’21”
What we found
Evidence strength A What the grades mean
The company stated on August 3, 2021, that it expected to begin enrolling a SER-155 clinical study soon, indicating the initiation occurred after the H1 2021 deadline.
-
A Seres Therapeutics, Inc. 8-K filed 2021-08-03
“Seres expects to soon begin enrolling a SER-155 Phase 1b clinical study” ✓ confirmed on the page
Market reaction: the shares moved -1.7% against the S&P 500 over the three sessions around the disclosure (2 Aug 2021 to 5 Aug 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Initiate
- Deliverable
- SER-155 clinical development
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Seres Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-MCRB-021548 · Corrections policy